Ibrahim Jalal - Hikma Pharmaceuticals Insider

Hikma Pharmaceuticals PLC -- UK Stock  

GBp 1,102  7.50  0.68%

Sr. Corporate VP of Technical Affairs

Dr. Ibrahim Jalal is Senior Corporationrationrate Vice President Technical Affairs of Hikma Pharmaceuticals Plc. Ibrahim joined Hikma as Technical Director and has held a variety of roles including Corporationrationrate Technical Vice President for Compliance and Senior Corporationrationrate Vice President for RD. He has played a leading role in Hikma securing FDA approval for its manufacturing units. Ibrahim holds a PhD in Pharmacy from the University of WisconsinMadison.
  VP Since 2008  Ph.D    
44 20 7399 2760  http://www.hikma.com

Management Efficiency

The company has return on total asset (ROA) of (12.05) % which means that it has lost $12.05 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (42.6) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 776 M in total debt with debt to equity ratio (D/E) of 50.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Hikma Pharmaceuticals PLC has Current Ratio of 1.94 which is within standard range for the sector.

Entity Summary

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. Hikma Pharmaceuticals PLC was founded in 1978 and is based in London, the United Kingdom. Hikma Pharmaceuticals operates under Pharmaceuticals And Biosciences classification in UK and traded on London Stock Exchange exchange.Hikma Pharmaceuticals PLC (HIK) is traded on London Stock Exchange in UK. It is located in 1 New Burlington Place and employs 7,189 people.

Did you try this?

Run Premium Stories Now

Premium Stories

Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Hide  View All  NextLaunch Premium Stories

Fix Portfolio

Optimize Your Risk-Return Tradeoff
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Hikma Pharmaceuticals PLC to your portfolio

Top Management

Hikma Pharmaceuticals Leadership Team
Fadi Nassar, President
Bassam Kanaan, Executive, CPA
Khalid Nabilsi, CFO, CPA
Hussein Arkhagha, Executive
Susan Ringdal, President, MBA
Pamela Kirby, Director, Ph.D
John Castellani, Director
Brian Hoffman, President, MBA
Ali AlHusry, Director, MBA
Jochen Gann, Director
Peter Speirs, Executive
Patrick Butler, Director
Said Darwazah, Chairman, MBA
Michael Raya, CEO
Ronald Goode, Director
Sigurdur Olafsson, CEO
Breffni Byrne, Director
Nina Henderson, Director
Ragheb AlShakhshir, President
Michael Ashton, Director, MBA
Majda Labadi, President
Ibrahim Jalal, VP, Ph.D
Riad Mishlawi, President
Robert Pickering, Director
Mazen Darwazah, Chairman

Stock Performance

Hikma Pharmaceuticals Performance Indicators